First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies
Chordoma is a rare tumor of notochordal origin, currently principally treated by surgery and/or irradiation. Here, we describe the clinical outcome of 3 consecutive patients with metastatic and locally advanced chordoma, treated with different immunotherapeutic approaches. All patients presented fas...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-08-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/2162402X.2017.1338235 |
| _version_ | 1818970324265336832 |
|---|---|
| author | Denis Migliorini Nicolas Mach Diego Aguiar Rémi Vernet Basile Nicolas Landis Minerva Becker Thomas McKee Valérie Dutoit Pierre-Yves Dietrich |
| author_facet | Denis Migliorini Nicolas Mach Diego Aguiar Rémi Vernet Basile Nicolas Landis Minerva Becker Thomas McKee Valérie Dutoit Pierre-Yves Dietrich |
| author_sort | Denis Migliorini |
| collection | DOAJ |
| description | Chordoma is a rare tumor of notochordal origin, currently principally treated by surgery and/or irradiation. Here, we describe the clinical outcome of 3 consecutive patients with metastatic and locally advanced chordoma, treated with different immunotherapeutic approaches. All patients presented fast growing tumors and failure of standard therapies. One was treated with a tumor-based vaccine, the 2 others with anti-PD1 antibodies, all with impressive clinical and radiological responses. We therefore propose that chordoma is an immunogenic tumor and thus that translational and clinical research is necessary to develop rationally designed immunotherapy approaches. |
| first_indexed | 2024-12-20T14:34:40Z |
| format | Article |
| id | doaj.art-15ba3ae834f14e8593c636f763cba911 |
| institution | Directory Open Access Journal |
| issn | 2162-402X |
| language | English |
| last_indexed | 2024-12-20T14:34:40Z |
| publishDate | 2017-08-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj.art-15ba3ae834f14e8593c636f763cba9112022-12-21T19:37:30ZengTaylor & Francis GroupOncoImmunology2162-402X2017-08-016810.1080/2162402X.2017.13382351338235First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapiesDenis Migliorini0Nicolas Mach1Diego Aguiar2Rémi Vernet3Basile Nicolas Landis4Minerva Becker5Thomas McKee6Valérie Dutoit7Pierre-Yves Dietrich8Geneva University HospitalGeneva University HospitalGeneva University HospitalGeneva UniversityGeneva University HospitalGeneva University HospitalGeneva University HospitalGeneva University HospitalGeneva University HospitalChordoma is a rare tumor of notochordal origin, currently principally treated by surgery and/or irradiation. Here, we describe the clinical outcome of 3 consecutive patients with metastatic and locally advanced chordoma, treated with different immunotherapeutic approaches. All patients presented fast growing tumors and failure of standard therapies. One was treated with a tumor-based vaccine, the 2 others with anti-PD1 antibodies, all with impressive clinical and radiological responses. We therefore propose that chordoma is an immunogenic tumor and thus that translational and clinical research is necessary to develop rationally designed immunotherapy approaches.http://dx.doi.org/10.1080/2162402X.2017.1338235chordomabrachyuryimmunotherapyimmune checkpoint inhibitorsmelanoma antigensneoantigentumor vaccine |
| spellingShingle | Denis Migliorini Nicolas Mach Diego Aguiar Rémi Vernet Basile Nicolas Landis Minerva Becker Thomas McKee Valérie Dutoit Pierre-Yves Dietrich First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies OncoImmunology chordoma brachyury immunotherapy immune checkpoint inhibitors melanoma antigens neoantigen tumor vaccine |
| title | First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies |
| title_full | First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies |
| title_fullStr | First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies |
| title_full_unstemmed | First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies |
| title_short | First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies |
| title_sort | first report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies |
| topic | chordoma brachyury immunotherapy immune checkpoint inhibitors melanoma antigens neoantigen tumor vaccine |
| url | http://dx.doi.org/10.1080/2162402X.2017.1338235 |
| work_keys_str_mv | AT denismigliorini firstreportofclinicalresponsestoimmunotherapyin3relapsingcasesofchordomaafterfailureofstandardtherapies AT nicolasmach firstreportofclinicalresponsestoimmunotherapyin3relapsingcasesofchordomaafterfailureofstandardtherapies AT diegoaguiar firstreportofclinicalresponsestoimmunotherapyin3relapsingcasesofchordomaafterfailureofstandardtherapies AT remivernet firstreportofclinicalresponsestoimmunotherapyin3relapsingcasesofchordomaafterfailureofstandardtherapies AT basilenicolaslandis firstreportofclinicalresponsestoimmunotherapyin3relapsingcasesofchordomaafterfailureofstandardtherapies AT minervabecker firstreportofclinicalresponsestoimmunotherapyin3relapsingcasesofchordomaafterfailureofstandardtherapies AT thomasmckee firstreportofclinicalresponsestoimmunotherapyin3relapsingcasesofchordomaafterfailureofstandardtherapies AT valeriedutoit firstreportofclinicalresponsestoimmunotherapyin3relapsingcasesofchordomaafterfailureofstandardtherapies AT pierreyvesdietrich firstreportofclinicalresponsestoimmunotherapyin3relapsingcasesofchordomaafterfailureofstandardtherapies |